Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
The Bone and Hormonal Milieu: Implications for Adjuvant Therapy
Fontainebleau Miami Beach Hotel
Miami, FL
March 6, 2009
Conference Overview
Oncology CME-Certified Symposium
Held in conjunction with the 26th Annual Miami Breast Cancer Conference
For patients with hormone receptor–positive early-stage breast cancer, both tamoxifen and aromatase inhibitors have dramatically improved disease outcome. However, significant risk of recurrence continues to persist long after completion of adjuvant endocrine therapy, suggesting that there is room for improvement in this area of breast cancer therapy. Recent recommendations suggest inclusion of an aromatase inhibitor at some point in the adjuvant treatment regimen for postmenopausal patients, although the optimal timing and duration of this therapy is still controversial. Additionally, bone complications present a frequent clinical challenge for patients with breast cancer. Many therapies used in treating patients with early-stage breast cancer can have a deleterious effect on bone density, leading to increased risk of fracture, requiring physicians to monitor the bone health status of their patients and be knowledgeable about optimal therapeutic strategies. Finally, bone-targeted agents might also have a direct effect on tumors, and several studies have suggested these agents might have utility in reducing the risk of metastases and disease progression. The Bone and Hormonal Milieu: Implications for Adjuvant Therapy symposium is designed to update physicians on the latest information regarding the safety and efficacy of hormonal therapies and bone-targeted therapies for early-stage breast cancer.
This educational program is directed toward medical oncologists, surgeons, and radiation oncologists interested in the treatment of breast cancer. Physician assistants, research nurses, and fellows interested in the treatment of patients with breast cancer are also invited to attend.At the conclusion of this symposium, you should be able to:
- Evaluate the use of bone-targeted agents for the prevention of treatment-induced bone loss and the prevention of bone metastases in patients with early-stage breast cancer
- Review the latest clinical data on adjuvant endocrine therapy, including up-front compared to switching strategies and extended therapy with selective estrogen receptor modulators and aromatase inhibitors
- Apply data from clinical trials and consensus guidelines to optimize choices concerning endocrine therapy and the management of bone health in early-stage breast cancer in defined clinical situations
Educational Grants
An educational grant for this activity was provided by:
- Novartis Oncology